J9171Docetaxel injection
Published CMS Medicare Part B payment-limit context for J9171, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$0.456
per 1 MG · Medicare Part B
Down 18.0%from $0.556 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$0.8487$0.3213
2024-Q4: $0.791; 2025-Q1: $0.734; 2025-Q2: $0.611; 2025-Q3: $0.379; 2025-Q4: $0.626; 2026-Q1: $0.651; 2026-Q2: $0.556; 2026-Q3: $0.456
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Docetaxel ingredient family (FDA data as of August 20, 2026).
Docetaxel
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Docetaxel presentations
3 other CMS codesSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J9172 | Docetaxel (docivyx), 1 mg | $46.287 per 1 MG | $50.607 per 1 MG | Down 8.5% | ||
| J9174 | Inj, docetaxel (beizray) 1mg | $46.808 per 1 MG | Not published | Not available | ||
| J9232 | Inj docetaxel (hospira) 1 mg | $0.512 per 1 MG | Not published | Not available |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.